Table 4

Combination of DART items and possible triggered type of medication review

DART item (translated from German)Outcome in statistical analysisPossible triggered clinical pharmacy service
I have a heart weakness/heart performance weakness.Correlated with DRPs with high clinical relevance.Consider immediate MRT3 inclusive of a patient interview.
I have trouble taking my medicine because of splitting tablets.Correlated with DRPs with high clinical relevance.Consider immediate MRT3 inclusive of a patient interview.
I use Marcoumar (phenprocoumon), Xarelto (rivaroxaban), Sintrom (acenocoumarol), Eliquis (apixaban), Lixiana (edoxaban) or Pradaxa (dabigatran) at home.Correlated with DRPs with high clinical relevance.Consider immediate MRT3 inclusive of a patient interview.
I use cortisone at home.Correlated with DRPs with moderate clinical relevance.Consider immediate MRT3 inclusive of a patient interview.
I have diabetes.Discriminated for cluster of patients with a high number of DRPs.Consider MRT3 inclusive of a patient interview.
I take more than five drugs every day, which are prescribed by my physician.Discriminated for cluster of patients with a high number of DRPs.Consider MRT3 inclusive of a patient interview.
Do you sometimes forget to take your medicine?Discriminated for cluster of patients with a high number of DRPs.Consider MRT3 inclusive of a patient interview.
I sometimes worry about becoming too dependent on my medicines.Discriminated for cluster of patients with a high number of DRPs.Consider MRT3 inclusive of a patient interview.
I use medicines against rheumatism/inflammation at home.Discriminated for cluster of patients with DRPs only identified in patient interview.Consider patient interview (MRT2a).
I use insulin/medicines against diabetes at home.Discriminated for cluster of patients with DRPs only identified in patient interview.Consider patient interview (MRT2a).
I use digoxin at home.Discriminated for cluster of patients with DRPs only identified in patient interview.Consider patient interview (MRT2a).
I sometimes worry about the long-term effects of my medicines.Discriminated for cluster of patients with DRPs only identified in patient interview.Consider patient interview (MRT2a).
Having to take this medicine worries me.Discriminated for cluster of patients with DRPs only identified in patient interview.Consider patient interview (MRT2a).
I apply my medication in the form of skin patches.Discriminated for cluster of patients with DRPs only identified in patient interview.Consider patient interview (MRT2a).
I have a restricted kidney function/kidney dysfunction/kidney disease.Discriminated for cluster of patients with DRPs only identified in patient interview.Consider patient interview (MRT2a).
The preparation of my medicine is done by a homecare institution.Discriminated for cluster of patients with DRPs only identified in patient interview.Consider patient interview (MRT2a).
  • MRT3, Medication Review Type 3; drug therapy evaluations using medical records, laboratory measurements, and the patient’s opinions and experiences. MRT2a, Medication Review Type 2a; drug therapy evaluations using medication history and the patient’s opinions and experiences.7

  • DART, Drug-Associated Risk Tool; DRPs, drug-related problems.